SAN DIEGO, May 6, 2026
Gallant, an emerging animal health biotechnology company focused on regenerative veterinary medicine, has announced significant progress in the development of its intravenous stem cell therapy for canine osteoarthritis (OA) following positive pilot study results and expanded eligibility under the FDA Center for Veterinary Medicine (FDA-CVM) conditional approval pathway. The company stated that the milestone could accelerate the commercialization timeline for its investigational mesenchymal stromal cell (MSC) therapy targeting one of the largest unmet medical needs in veterinary healthcare.
Gallant Receives Expanded FDA-CVM Approval Pathway Eligibility
Gallant confirmed that its canine osteoarthritis MSC therapy program has received eligibility for the FDA-CVM’s expanded conditional approval pathway, which is designed to support earlier access to innovative therapies addressing serious animal health conditions. The company is targeting potential conditional approval for the therapy by 2028, marking a major regulatory advancement for regenerative veterinary medicine.
According to Gallant, osteoarthritis remains one of the most widespread yet underdiagnosed diseases affecting dogs globally. The company noted that more than 20% of dogs over one year of age, approximately 40% of dogs over four years old, and up to 80% of dogs older than eight years are affected by OA. Researchers increasingly recognize that inflammatory immune processes play a central role in the progression of the disease, moving beyond the traditional belief that osteoarthritis is simply an age-related degenerative condition.
Gallant’s therapy utilizes uterine-derived mesenchymal stromal cells (UMSCs) designed to target immune dysregulation and inflammatory pathways linked to cartilage degeneration and chronic joint pain. The company believes its regenerative medicine platform could help transform veterinary osteoarthritis treatment by addressing the root biological causes of disease progression rather than only managing symptoms.
Advertisement
Pilot Study Demonstrates Improved Mobility and Quality of Life
The randomized, blinded, placebo-controlled pilot study enrolled 88 client-owned dogs diagnosed with radiographically confirmed osteoarthritis and visible pain or lameness in at least one affected joint. Participating dogs received either two intravenous doses of Gallant’s UMSC therapy or saline placebo injections administered two weeks apart, with evaluations continuing through Day 90.
Gallant reported that dogs treated with the investigational stem cell therapy demonstrated statistically significant improvement compared with placebo across multiple validated pet-owner outcome measurements at both Day 60 and Day 90. Assessments involving mobility, pain reduction, and overall quality of life consistently favored dogs receiving the IV-delivered UMSC therapy.
Importantly, the company stated that no treatment-related serious adverse events were observed during the study, supporting the potential safety profile of repeated intravenous dosing using donor-derived mesenchymal stromal cells. Dr. Rebecca Windsor, Vice President of Veterinary Affairs at Gallant, stated that the early findings demonstrated encouraging signals across key clinical outcomes while supporting the long-term therapeutic potential of regenerative stem cell treatment in canine OA management.
IV Stem Cell Delivery Could Expand Veterinary Access
A major differentiator in Gallant’s therapeutic approach is the use of intravenous administration rather than direct joint injection procedures commonly associated with traditional cell therapies. The company explained that intra-articular injection methods often require sedation, anesthesia, specialized training, or referral to veterinary specialists, limiting accessibility for many pet owners and veterinary clinics.
Gallant’s ready-to-use, off-the-shelf IV-delivered MSC therapy is designed for broader accessibility across general veterinary practices, potentially allowing more veterinarians to provide regenerative treatment options for dogs suffering from chronic osteoarthritis. Company CEO Dr. Linda Black described the development as another important step toward revolutionizing OA treatment in veterinary medicine and expanding practical access to regenerative care.
The company continues to position regenerative medicine as a future cornerstone of animal healthcare, with ongoing efforts focused on advancing stem cell therapies capable of restoring health by targeting the underlying biological mechanisms responsible for chronic disease progression in companion animals.
Source: Gallant press release
